EMERYVILLE, Calif., May 21, 2020 (GLOBE NEWSWIRE) — Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and […]
Progress Reported in Both Proprietary and Partnered Neurology Clinical Programs Additional FDA Feedback Supports Commencement of XEN496 Phase 3 Clinical Trial […]